Here are four things to know.
1. The agency stopped the phase two clinical trial before patient dosing began, requesting more data on toxicology studies to support the one-year planned dosing for the trial, reports MarketWatch.
2. Concert said the clinical hold did not stem from any safety concerns involving the drug.
3. The drugmaker plans to submit the requested information to the FDA soon. Once submitted, the agency will have 30 days to review the information and decide whether to lift the clinical hold.
4. Concert is competing with Aclaris Therapeutics, who is developing a similar hair loss drug, to receive the first FDA approval for an alopecia areata treatment, reports Reuters.
More articles on supply chain:
Viewpoint: Why healthcare needs more ‘me too’ drugs
FDA safety warning: Diabetes drug causes higher risk of foot, leg amputations
Senate health commitee OKs FDA user fee reauthorization bill
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
